ADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull Thesis

ADC Therapeutics' restructuring extends cash runway to 2029, but Zynlonta safety/regulatory risks loom. Click here to read ...

Ascent Industries: A Lot Of Potential, But Needs To Work On Cash Flow And Profitability

Ascent Industries (ACNT) shifts to specialty chemicals; Q2 FY26 sales +38% and EBITDA margin 5.7%, but cash burn persists.
Mashable

I tested all of Amazon's e-readers, and this is the best Kindle to buy

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Credit: Samantha Mangino / ...